ClostraBio will present at the 14th Annual Biotech Showcase Event

CHICAGO, Jan. 10, 2022 /PRNewswire-PRWeb/ — ClostraBio, Inc. today announced that the company will be presenting a research and development update on its lead compound CLB-004 as well as the start of its Series A investment round at the Biotech Showcase™ 2022 conference from January 10-12 and 17-19. ClostraBio is a preclinical stage company focused on targeted metabolite delivery to transform intestinal health in patients with inflammatory bowel disease (IBD) and food allergy.

“Following our admission into the Portal Innovations venture portfolio – ClostraBio has strategically focused its drug development efforts and accelerated its timeline to the clinic,” said Cathryn Nagler, PhD, president and co-founder of ClostraBio, and Bunning Family Professor in the Pritzker School of Molecular Engineering, the Department of Pathology, University of Chicago. “We remain committed to developing novel, differentiated oral dosage forms to help patients with uncontrolled IBD and food allergy who need non-immunosuppressive treatment options.”

In the last year, ClostraBio has made significant progress in demonstrating initial safety and efficacy of its lead compound CLB-004 in multiple preclinical models. The company intends to use this data to raise a Series A investment round and advance CLB-004 into a Phase 1a/b clinical study in patients with mild-moderate ulcerative colitis. With an IND-enabling toxicology program underway, the company is currently planning a pre-IND interaction with FDA in the first half of 2022.

Biotech Showcase 2022, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities.

The recorded presentation by Brett Newswanger, the company’s Chief Operating Officer, will take place virtually and registered attendees to Biotech Showcase can access ClostraBio’s presentation with 24×7 on-demand access, allowing attendees to view the presentation at their convenience at https://informaconnect.com/biotech-showcase/.

“We are delighted that ClostraBio will be presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”

ABOUT CLOSTRABIO
ClostraBio is a preclinical stage company focused on targeted metabolite delivery to transform intestinal health in patients with IBD and food allergy. As a spin out of the Nagler and Hubbell labs at the University of Chicago, the company is developing a proprietary polymer platform that enables oral delivery of short-chain fatty acids (SCFAs) to targeted locations in the distal gut. In healthy individuals, commensal clostridial bacteria ferment fiber to produce SCFAs such as butyrate, however people with IBD or food allergy are dysbiotic, meaning they lack these healthy bacteria, have decreased levels of SCFAs, and therefore show impaired epithelial barrier function which is a key contributor to disease. ClostraBio’s proprietary polymers (CLB-004) are intended to deliver butyrate to the distal gut, thus mimicking commensal bacteria, to help restore barrier function and stabilize the gut microbiome. For more information about the company, please visit: http://clostrabio.com

ABOUT PORTAL INNOVATIONS
Portal Innovations is a premier venture development engine that bridges scientific ideation in life sciences, medtech and bioinformatics innovation through commercial proof of concept by delivering seed capital, fully equipped lab space and management expertise to high-potential early-stage companies addressing underserved human health challenges.

ABOUT BIOTECH SHOWCASE
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 14th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.

CONTACTS:
Brett Newswanger, COO
brett.newswanger@clostrabio.com
ClostraBio, Inc.

Follow ClostraBio on Twitter at @Clostrabio and Biotech Showcase at @EBDGroup and @Demy_Colton and tag your posts with #BiotechShowcase.

Media Contact

Brett Newswanger, ClostraBio, Inc., +1 720-560-5580, brett.newswanger@clostrabio.com

SOURCE ClostraBio, Inc.